The jury made this award on the basis that the company, Wyeth, failed to warn about the risks of the drug and took only minutes to come to their decision.
On 15 March, 2010 Pfizer announced that they have stopped a phase-III trial of their monoclonal antibody Figitumumab and two trials of Sunitinib in breast cancer after they failed to show significant improvement in survival rates.
This is not a definitive study, but as most people in the West eat more protein than their body actually needs, it does indicate that lower protein diets could mean a lower risk of developing cancer and more research is certainly needed into this.
HRT has mainly been associated with hormonal cancer risks, but this study also links it to an increased lung cancer risk, and not just in smokers.